Literature DB >> 21132505

Electroconvulsive therapy for treating schizophrenia: a chart review of patients from two catchment areas.

Diana Kristensen1, Jeanett Bauer, Ida Hageman, Martin Balslev Jørgensen.   

Abstract

To examine disease and treatment characteristics of patients with schizophrenia treated with electroconvulsive therapy (ECT). We examined charts from 79 patients diagnosed with schizophrenia (n = 55), persistent delusional disorders (n = 7), and schizoaffective disorders (n = 17) between 2003 and 2008. We recorded age, sex, indication for ECT, number of ECT sessions, ECT series, outcome, maintenance ECT, use of antipsychotics, duration of illness, and duration of the current exacerbation. All patients were taking antipsychotics at the time of enrolment in the study. Acute ECT included 2-26 sessions; maintenance ECT (M-ECT) was given to 18 patients for up to 12 years. Initial indications for ECT included psychosis (n = 28), pronounced affective symptoms (n = 28), delirious states (n = 20), and M-ECT (n = 3). Most patients experienced excellent/good outcomes (n = 66), but others experienced moderate (n = 8) or poor (n = 5) outcomes. No factors were identified that predicted treatment responses in individual patients. ECT proved to be effective in a population of patients that were severely ill with treatment-refractory schizophrenia. This does not imply that the patients were cured from schizophrenia. Rather, it reflects the degree of relief from psychosis and disruptive behaviour, as described in the patient charts. The treatment was often offered to patients after considerable disease durations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21132505     DOI: 10.1007/s00406-010-0173-3

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  26 in total

Review 1.  ECT for treatment-resistant schizophrenia: a response from the far East to the UK. NICE report.

Authors:  Worrawat Chanpattana; Chittaranjan Andrade
Journal:  J ECT       Date:  2006-03       Impact factor: 3.635

2.  Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial.

Authors:  Wai-Kwong Tang; Gabor S Ungvari
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-05       Impact factor: 5.067

3.  Electroconvulsive therapy in first-episode schizophrenia.

Authors:  Alp Uçok; Sibel Cakir
Journal:  J ECT       Date:  2006-03       Impact factor: 3.635

Review 4.  Meta-analysis of initial seizure thresholds in electroconvulsive therapy.

Authors:  Jeroen A van Waarde; Bastiaan Verwey; Rose C van der Mast
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-04-21       Impact factor: 5.270

5.  Maintenance electroconvulsive therapy in affective and schizoaffective disorder.

Authors:  E Swoboda; A Conca; P König; R Waanders; M Hansen
Journal:  Neuropsychobiology       Date:  2001-01       Impact factor: 2.328

6.  Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia.

Authors:  Kazumasa Suzuki; Shuichi Awata; Takehisa Takano; Yukio Ebina; Hitoshi Iwasaki; Hiroo Matsuoka
Journal:  Psychiatry Clin Neurosci       Date:  2005-08       Impact factor: 5.188

7.  Combined ECT and neuroleptic therapy in treatment-refractory schizophrenia: prediction of outcome.

Authors:  W Chanpattana; M L Chakrabhand
Journal:  Psychiatry Res       Date:  2001-12-15       Impact factor: 3.222

8.  Gender-related features of persistent delusional disorders.

Authors:  Tobias Wustmann; Frank Pillmann; Andreas Marneros
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-08-12       Impact factor: 5.270

Review 9.  The many varieties of catatonia.

Authors:  M Fink; M A Taylor
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001       Impact factor: 5.270

10.  [Maintenance electroconvulsive therapy and treatment of refractory schizophrenia].

Authors:  M Lévy-Rueff; A Jurgens; H Lôo; J-P Olié; I Amado
Journal:  Encephale       Date:  2008-01-11       Impact factor: 1.291

View more
  7 in total

1.  Differential diagnosis of major depression and bipolar disorder.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-03       Impact factor: 5.270

2.  Combined Antipsychotics and Electroconvulsive Therapy in an Acutely Psychotic Patient with Treatment-resistant Schizophrenia.

Authors:  Ruth Rayikanti; Iga Lentowicz; Badari Birur; Li Li
Journal:  Psychopharmacol Bull       Date:  2017-05-15

Review 3.  Electroconvulsive Therapy and Schizophrenia: A Systematic Review.

Authors:  Sana A Ali; Nandita Mathur; Anil K Malhotra; Raphael J Braga
Journal:  Mol Neuropsychiatry       Date:  2019-04-02

4.  Clinical Effectiveness of Maintenance Electroconvulsive Therapy in Patients with Schizophrenia: A Retrospective Cohort Study.

Authors:  Moshe Isserles; Jesse Remington; Tyler S Kaster; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  J ECT       Date:  2020-03       Impact factor: 3.692

5.  Factors associated with the risk of relapse in schizophrenic patients after a response to electroconvulsive therapy: a retrospective study.

Authors:  Chiyo Shibasaki; Minoru Takebayashi; Yasutaka Fujita; Shigeto Yamawaki
Journal:  Neuropsychiatr Dis Treat       Date:  2015-01-05       Impact factor: 2.570

6.  Electroconvulsive shock attenuated microgliosis and astrogliosis in the hippocampus and ameliorated schizophrenia-like behavior of Gunn rat.

Authors:  Erlyn Limoa; Sadayuki Hashioka; Tsuyoshi Miyaoka; Keiko Tsuchie; Ryosuke Arauchi; Ilhamuddin A Azis; Rei Wake; Maiko Hayashida; Tomoko Araki; Motohide Furuya; Kristian Liaury; Andi J Tanra; Jun Horiguchi
Journal:  J Neuroinflammation       Date:  2016-09-02       Impact factor: 8.322

7.  The Effects of Continuation-Maintenance Electroconvulsive Therapy on Reducing Hospital Re-Admissions in Patients with Treatment-Resistant Schizophrenia.

Authors:  Kyung Mook Choi; Soo-Hee Choi; Jung Kyung Hong; Mi Hyun Lee; Joon Hyung Jung; Sang Hoon Oh; Dong Chung Jung; Sung Nyun Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-08-31       Impact factor: 2.582

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.